Teva Pharmaceuticals USA 2022-01-19 Health serious FDA
Health · FDA · Recall #FDA-D-0370-2022
MethylPREDNISolone Acetate Injectable Suspension USP 400 mg/10mL (40mg/mL), 10 mL… Recall
Issued January 19, 2022 · Teva Pharmaceuticals USA
In January 2022, Teva Pharmaceuticals USA recalled the MethylPREDNISolone Acetate Injectable Suspension USP 400 mg/10mL (40mg/mL), 10 mL…, a serious health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Lack of Assurance of Sterility
What you should do
- 1 Stop using MethylPREDNISolone Acetate Injectable Suspension USP 400 mg/10mL (40mg/mL), 10 mL… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Teva Pharmaceuticals USA to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Teva Pharmaceuticals USA
- Category
- Health
- Recall date
- January 19, 2022
- Units affected
- Not reported
- Sold at
- Methylprednisolone, TN Norepinephrine BItartrate - MS, OH
- Recall number
- FDA-D-0370-2022
- Made in
- United States
- Issuing agency
- FDA
In context
- Teva Pharmaceuticals USA has 4 recalls in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 870th Health recall we've logged in 2022.